Saxenda vs Ozempic: full weight loss comparison

Saxenda and Ozempic are both GLP-1 receptor agonists made by Novo Nordisk. They work through the same pathway but deliver very different results. Semaglutide (the active ingredient in Ozempic) produces roughly twice the weight loss of liraglutide (Saxenda) in clinical trials, costs less per month, and requires only one injection per week instead of one per day [1][2].

If you’re comparing these two medications as part of a weight loss treatment plan, the clinical data makes the choice fairly straightforward for most people. Here’s what the research actually shows.

Quick comparison table

This table summarizes the key differences. Scroll down for the clinical data behind each number.

Feature	Saxenda (liraglutide)	Ozempic (semaglutide)
Drug class	GLP-1 receptor agonist	GLP-1 receptor agonist
FDA-approved for weight loss	Yes (as Saxenda)	No (approved for T2D; Wegovy is the weight loss version)
Injection frequency	Once daily	Once weekly
Average weight loss	~8% of body weight	~15% of body weight
Key trial	SCALE (2015)	STEP 1 (2021)
Common side effects	Nausea (39%), diarrhea (21%), constipation (19%)	Nausea (44%), diarrhea (31%), vomiting (25%)
Monthly cost (retail)	~$1,300	~$900–$1,000
Compounded alternative available	No	Yes (~$299–$399/mo)

Key differences

Both drugs mimic the GLP-1 hormone that your gut releases after eating. They slow gastric emptying, reduce appetite, and signal fullness to the brain. The difference is potency and pharmacokinetics.

Semaglutide has a much longer half-life (about 7 days vs. 13 hours for liraglutide), which is why it works as a weekly injection [3]. That longer duration also means more sustained appetite suppression throughout the week.

A 2026 Bayesian network meta-analysis comparing liraglutide, semaglutide, and tirzepatide in patients with obesity found semaglutide 2.4 mg produced significantly greater weight reduction than liraglutide 3.0 mg across all measured outcomes [4]. The results weren’t close.

How Saxenda works

Saxenda (liraglutide 3.0 mg) was FDA-approved for weight management in 2014. It’s a daily subcutaneous injection that you self-administer, typically in the abdomen, thigh, or upper arm. The dose starts at 0.6 mg and increases weekly until reaching the maintenance dose of 3.0 mg.

The landmark SCALE Obesity and Prediabetes trial enrolled 3,731 adults and ran for 56 weeks. Participants on liraglutide 3.0 mg lost an average of 8.0% of their body weight, compared to 2.6% with placebo. About 63% of liraglutide patients lost at least 5% of their body weight [1].

A 2025 Cochrane systematic review confirmed these findings across multiple trials, noting that liraglutide produces “modest but clinically meaningful” weight loss [5]. The review also flagged that gastrointestinal side effects cause a notable percentage of patients to discontinue treatment.

For patients considering other peptide-based approaches to fat loss, Saxenda was the gold standard GLP-1 option until semaglutide arrived.

Liraglutide also showed benefits beyond the scale. In the SCALE trial, patients on liraglutide had greater reductions in waist circumference, fasting glucose, and systolic blood pressure compared to placebo. About 14% of prediabetic patients on liraglutide converted to type 2 diabetes over three years, compared to 22% on placebo [1].

How Ozempic works

Ozempic (semaglutide) is FDA-approved for type 2 diabetes at doses up to 2.0 mg weekly. Its weight-loss sibling, Wegovy, uses the same molecule at 2.4 mg and is specifically approved for weight management. In practice, many doctors prescribe Ozempic off-label for weight loss.

The STEP 1 trial tested semaglutide 2.4 mg in 1,961 adults without diabetes over 68 weeks. The semaglutide group lost an average of 14.9% of their body weight, compared to 2.4% with placebo. Roughly 86% of participants lost at least 5%, and one-third lost 20% or more [2].

That 14.9% average puts semaglutide in a different category from liraglutide. For context, bariatric surgery typically produces 20-30% weight loss. Semaglutide closed a significant portion of that gap with a weekly injection.

The mechanism is the same GLP-1 receptor activation, but semaglutide binds more tightly to the receptor and resists enzymatic breakdown more effectively than liraglutide. These molecular differences explain the gap in clinical results [3].

If you’re weighing your options between different GLP-1 medications, our comparison of semaglutide vs tirzepatide covers the next tier of this decision.

Side effects comparison

Both drugs share the same core side effect profile because they target the same receptor. Gastrointestinal symptoms dominate.

Nausea is the most common complaint with both medications. In clinical trials, 39% of Saxenda patients and 44% of Ozempic patients reported nausea [1][2]. The difference is that Ozempic’s nausea tends to be more intense during the dose-escalation phase but often resolves faster because the weekly dosing schedule is simpler to titrate.

Diarrhea affected 21% of Saxenda users and 31% of semaglutide users in their respective trials. Vomiting was more common with semaglutide (25% vs. 16%).

Pancreatitis is a rare but serious risk with both drugs. The incidence is low (less than 0.5% in both trial programs), but both carry black-box warnings about medullary thyroid carcinoma based on rodent studies [1][2].

Discontinuation rates due to side effects were 9.8% for liraglutide in the SCALE trial and 7.0% for semaglutide in STEP 1. Despite more intense GI symptoms, semaglutide patients were more likely to stay on treatment, possibly because the weekly dosing was easier to manage.

Gallbladder issues deserve mention. Both drugs increase the risk of gallstones and cholecystitis, likely because rapid weight loss of any kind stresses the gallbladder. The risk is dose-dependent and shows up more often with semaglutide’s greater weight loss.

One thing neither drug avoids: when you stop taking it, most of the weight comes back. A STEP 1 extension study showed participants regained about two-thirds of their lost weight within a year of discontinuation. That’s not unique to GLP-1s. It reflects the biology of obesity: your body defends its highest sustained weight through hormonal changes that persist long after the weight is lost.

Cost comparison

This is where the math gets uncomfortable for Saxenda.

Saxenda’s retail price runs approximately $1,300 per month without insurance. Ozempic (for diabetes) costs roughly $900–$1,000 per month at retail. Wegovy, the weight-loss formulation of semaglutide, runs about $1,300–$1,400 per month [6].

So you’re looking at similar prices for Saxenda and Wegovy, but Ozempic is somewhat cheaper when prescribed off-label.

Here’s the real cost difference: compounded semaglutide is available through telehealth providers like Pure Peptide Clinic for $299–$399 per month. There is no compounded liraglutide alternative widely available. That makes the out-of-pocket cost comparison roughly $1,300/month (Saxenda) vs. $299–$399/month (compounded semaglutide).

Insurance coverage varies wildly. Many commercial plans cover Ozempic for diabetes but not for weight loss. Saxenda has broader weight-loss coverage in theory, but prior authorization requirements make access unpredictable. Check your specific plan before assuming either will be covered.

The Novo Nordisk savings card can reduce Saxenda costs to as low as $25/month for eligible commercially insured patients, but that program excludes Medicare, Medicaid, and uninsured patients.

Find out which GLP-1 is right for you →

Who should choose what

Saxenda may be a better fit if:

• Your insurance covers it but not semaglutide for weight loss
• You’ve tried semaglutide and couldn’t tolerate the side effects (some patients do better on the older drug)
• You prefer the ability to fine-tune your dose daily

Ozempic/semaglutide is likely the better choice if:

• You want maximum weight loss from a GLP-1
• You’d rather inject once a week than once a day
• You’re paying out of pocket (compounded semaglutide is far cheaper)
• Your doctor is comfortable prescribing it off-label

For patients who need even more weight loss, tirzepatide (Mounjaro/Zepbound) adds GIP receptor activation on top of GLP-1 and has produced up to 22.5% weight loss in trials [7]. It’s the next step up in the GLP-1 hierarchy.

Our drug comparison hub breaks down all FDA-approved weight loss medications side by side if you want the complete picture.

FAQ

Is Ozempic the same thing as Wegovy?▼

Same active ingredient (semaglutide), different doses and FDA approvals. Ozempic is approved for type 2 diabetes at up to 2.0 mg weekly. Wegovy is approved for weight management at 2.4 mg weekly. Many doctors prescribe Ozempic off-label for weight loss at the diabetes dose, though the full 2.4 mg dose used in weight loss trials isn’t available in the Ozempic pen.

Can I switch from Saxenda to Ozempic?▼

Yes. Your doctor can transition you directly, though you’ll typically start semaglutide at the lowest dose (0.25 mg weekly) and titrate up over 4-5 weeks regardless of your previous Saxenda dose. The GLP-1 receptor tolerance you built on liraglutide may help reduce initial nausea on semaglutide [3].

Why is Saxenda a daily injection but Ozempic is weekly?▼

The difference is molecular. Semaglutide has structural modifications that make it bind more tightly to albumin in the blood, which dramatically slows its clearance. Liraglutide’s half-life is about 13 hours, so it needs daily dosing. Semaglutide’s half-life is roughly 7 days, allowing once-weekly administration [3].

Does Saxenda work for people who don’t respond to Ozempic?▼

There’s limited evidence either way. Since both drugs target the same GLP-1 receptor, a poor response to one generally predicts a poor response to the other. If semaglutide at 2.4 mg hasn’t produced meaningful weight loss, liraglutide at 3.0 mg is unlikely to do better. Switching to a dual-agonist like tirzepatide is a more logical next step.

Is compounded semaglutide as effective as brand-name Ozempic?▼

Compounded semaglutide contains the same active molecule and, when sourced from a licensed 503A or 503B pharmacy, should produce equivalent results. The FDA has raised concerns about quality control at some compounding pharmacies, so choosing a provider that uses verified pharmacies matters. Learn more about whether compounded semaglutide is safe.

How much weight will I actually lose on each drug?▼

Trial averages are 8% on Saxenda and 15% on Ozempic/Wegovy, but individual results vary significantly. About 37% of Saxenda patients and 14% of Ozempic patients lost less than 5% of their body weight in trials [1][2]. Factors like diet, exercise, starting weight, and genetics all affect outcomes.

Are there oral versions of these drugs?▼

Oral semaglutide (Rybelsus) exists for type 2 diabetes but hasn’t been approved at weight-loss doses yet. Novo Nordisk is testing a higher-dose oral semaglutide pill for obesity. There is no oral liraglutide. For now, if you want to avoid injections entirely, the options are older medications like Contrave or Qsymia.

Check if you qualify for GLP-1 treatment →

References

1. Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. PubMed

2. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed

3. Mahapatra MK, et al. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022;23(3):521-539. PubMed

4. Ciudin A, et al. Comparison of clinical efficacy and safety of tirzepatide, liraglutide and semaglutide in patients with obesity and without T2D: a Bayesian network meta-analysis of randomised controlled trials. Adv Ther. 2026. PubMed

5. Liraglutide for adults living with obesity. Cochrane Database Syst Rev. 2025. PubMed

6. Comparison table: Some drugs for weight management. Med Lett Drugs Ther. 2025;67(1734). PubMed

7. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed